Feasibility Study of Uterine Transplantation From Living Donors in Terms of Efficacy and Safety in Patients With Mayer-Rokitansky-Küster-Hauser Syndrome (MRKH)

  • End date
    Jun 1, 2025
  • participants needed
  • sponsor
    Hopital Foch
Updated on 14 February 2022
Accepts healthy volunteers


In France, one in 4500 women is affected by the MayerRokitantskyKsterHauser (MRKH) syndrome which is characterized by the absence of uterus at birth. Currently, the only solutions for these patients are:

  • Gestational surrogacy, prohibited in France
  • Adoption
  • Resignation

Uterine transplantation could become a good alternative.

This study is conducted in 10 patients with MRKH type I syndrome, who will be transplanted from a living donor uterus


The aim of the study is to obtain a pregnancy after uterine transplantation from a living donor. Also, this study will assess (anatomically and functionally) the issue of the transplants of a uterus taken from a living donor and the safety of the living donor (functionally and psychologically)

Condition Mayer Rokitansky Kuster Hauser Syndrome
Treatment Uterine transplantation
Clinical Study IdentifierNCT03689842
SponsorHopital Foch
Last Modified on14 February 2022


Yes No Not Sure

Inclusion Criteria

Graft recipient is a patient with Mayer-Rokitansky-Kster-Hauser Type I Uterine
Vaginal Agenesis (without renal, cardiac and bone malformations)
Being aged between 18 and 38 years old
In stable couple, with a pregnancy project, favorable psychological evaluation
No history of cancer and transfusion
The living donor is a woman related to the Graft recipient with
Absence of comorbidity (neurological, nephro-urological pathology, infectious, psychiatric or psychological pathology)
Absence of uterine surgery, abdomino-pelvic major pathology history

Exclusion Criteria

Graft recipient
Extreme oligo-astheno-spermia and azoospermia in the husband
History of abdominopelvic surgery excluding uncomplicated appendectomy; vaginal residue not allowing anastomosis
Living donor
Known thromboembolic risk factor
No Compatibility with the recipient (group, rhesus, HLA)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note